Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?

Caminati, Marco; Guarnieri, Gabriella; Senna, Gianenrico

Caminati, Marco; Guarnieri, Gabriella; Senna, Gianenrico.

Caminati M; Department of Medicine, University of Verona and Verona University Hospital, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.
Guarnieri G; Respiratory Pathophysiology Unit, Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padova, 35121 Padova, Italy.
Senna G; Department of Medicine, University of Verona and Verona University Hospital, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.

Vaccines (Basel) ; 9(1)2021 Jan 11.

Article in English | MEDLINE | ID: covidwho-1022027

ABSTRACT

ABSTRACT

The vaccination campaign against the Severe acute respiratory syndrome coronavirus 2 (Sars-Cov-2) started on 8 December 2020 in UK, after the approval of BNT162b2 by the Healthcare products Regulatory Agency (MHRA) [...].

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines Language: English Year: 2021 Document Type: Article Affiliation country: Vaccines9010038

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google